Physician profile

Chadi Kaba

Internal Medicine · Attleboro, MA

NPI 1811945694

$1,454.77

in general payments reported to CMS, 2019-2025

15 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pfizer INC. $382.21 2019-2021
Novo Nordisk INC $231.16 2019-2020
Glaxosmithkline, LLC. $213.95 2019-2021
Janssen Pharmaceuticals, INC $118.81 2019-2021
Astrazeneca Pharmaceuticals LP $89.72 2020-2021
Lilly USA, LLC $78.55 2019-2020
Amgen INC. $76.34 2019-2020
Astellas Pharma US INC $57.80 2019
Sanofi-Aventis U.S. LLC $46.44 2020-2021
Abbvie INC. $36.68 2020
Merck Sharp & Dohme LLC $35.29 2019
Novartis Pharmaceuticals Corporation $28.74 2019-2021
Mylan Specialty L.P. $22.20 2020
E.R. Squibb & Sons, L.L.C. $20.33 2019
Sanofi Pasteur INC. $16.55 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Chadi Kaba

$1,454.77

in general payments reported 2019-2025

Years
2019-2021
Top company
Pfizer INC.

https://glasscript.com/doctor/898571/chadi-kaba

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.